Benign Prostatic Hyperplasia – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Benign Prostatic Hyperplasia – Pipeline Review, H1 2017’, provides an overview of the Benign Prostatic Hyperplasia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Benign Prostatic Hyperplasia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Benign Prostatic Hyperplasia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Benign Prostatic Hyperplasia

– The report reviews pipeline therapeutics for Benign Prostatic Hyperplasia by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Benign Prostatic Hyperplasia therapeutics and enlists all their major and minor projects

– The report assesses Benign Prostatic Hyperplasia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Benign Prostatic Hyperplasia

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Benign Prostatic Hyperplasia

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Benign Prostatic Hyperplasia pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Addex Therapeutics Ltd

AndroScience Corp

Aphios Corp

BCWorld Pharm Co Ltd

Biolab Farmaceutica Ltda

Chong Kun Dang Pharmaceutical Corp

Curadis GmbH

Dongkook Pharmaceutical Co Ltd

GL Pharm Tech Corp

Hanmi Pharmaceuticals Co Ltd

Health Ever Bio-Tech Co Ltd

Jeil Pharmaceutical Co Ltd

Kaken Pharmaceutical Co Ltd

MEI Pharma Inc

Meiji Seika Pharma Co Ltd

Mezzion Pharma Co Ltd

Monosol Rx LLC

Nymox Pharmaceutical Corp

Ono Pharmaceutical Co Ltd

OPKO Health Inc

SK Chemicals Co Ltd

SOM Biotech SL

Sophiris Bio Inc

Vantia Therapeutics

XuanZhu Pharma Co Ltd

Yungjin Pharm Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Benign Prostatic Hyperplasia - Overview

Benign Prostatic Hyperplasia - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Benign Prostatic Hyperplasia - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Benign Prostatic Hyperplasia - Companies Involved in Therapeutics Development

Addex Therapeutics Ltd

AndroScience Corp

Aphios Corp

BCWorld Pharm Co Ltd

Biolab Farmaceutica Ltda

Chong Kun Dang Pharmaceutical Corp

Curadis GmbH

Dongkook Pharmaceutical Co Ltd

GL Pharm Tech Corp

Hanmi Pharmaceuticals Co Ltd

Health Ever Bio-Tech Co Ltd

Jeil Pharmaceutical Co Ltd

Kaken Pharmaceutical Co Ltd

MEI Pharma Inc

Meiji Seika Pharma Co Ltd

Mezzion Pharma Co Ltd

Monosol Rx LLC

Nymox Pharmaceutical Corp

Ono Pharmaceutical Co Ltd

OPKO Health Inc

SK Chemicals Co Ltd

SOM Biotech SL

Sophiris Bio Inc

Vantia Therapeutics

XuanZhu Pharma Co Ltd

Yungjin Pharm Co Ltd

Benign Prostatic Hyperplasia - Drug Profiles

(dutasteride + tadalafil) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(solifenacin succinate + tamsulosin hydrochloride) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(tadalafil + tamsulosin hydrochloride) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(tadalafil + tamsulosin hydrochloride) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ADX-68692 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ASC-JM.X2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AUS-131 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BCWPE-004 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BL-214 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CR-1447 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fadanafil - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fedovapagon - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fexapotide triflutate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KKM-1202 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

L-1AD3 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MCS-2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NCE-403 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ONO-8430506 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

S-0131632 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

S-40542 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Steroidal 5-Alpha Reductase for Benign Prostatic Hyperplasia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SOM-2391 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SOM-2393 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Sperol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide to Antagonize GPR54 for Womens Health, Male Health and Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tadalafil - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

talaporfin sodium - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tamsulosin hydrochloride CR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tamsulosin hydrochloride DR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tamsulosin hydrochloride SR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tertomotide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

topsalysin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TT-701 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

udenafil - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

YBH-1603 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

YOB-1604 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Benign Prostatic Hyperplasia - Dormant Projects

Benign Prostatic Hyperplasia - Discontinued Products

Benign Prostatic Hyperplasia - Product Development Milestones

Featured News & Press Releases

May 08, 2017: NYMOX Files For Approval of First In Class Prostate Drug in Europe

May 03, 2017: NYMOX Files For Marketing Approval For Fexapotide Triflutate in Europe

Mar 29, 2017: Nymox Provides Update on Fexapotide Development

Dec 14, 2016: CFDA Granted Approval forPhase I/II/III Clinical Trials of Sihuan Pharmaceutical’s Internally Developed Innovative Patented New Drug - Fadanafil

Nov 29, 2016: Nymox Reports Additional Positive Results From Completed Fexapotide BPH Phase 3 Studies Showing Significant Early Response and First-Line Efficacy

Sep 20, 2016: Addex collaborators publish new data on negative allosteric modulator ADX68692

May 05, 2016: Sophiris Bio To Present Topsalysin Phase 3 Data from Positive PLUS-1 Study as a Late Breaking Poster During the 111th American Urological Association Annual Meeting

Apr 01, 2015: Nymox Announces Phase 3 BPH Studies

Dec 15, 2014: Sophiris Bio Reports Administrative Interim Analysis for the "PLUS-1" Phase 3 Trial of PRX302 for Benign Prostatic Hyperplasia

Nov 02, 2014: Nymox NX-1207 BPH Pivotal Phase 3 U.S. Studies NX02-0017 and NX02-0018 Fail to Meet Primary Efficacy Endpoints

Sep 02, 2014: Sophiris Bio Reports Completion of Enrollment in the "PLUS-1" Phase 3 Trial of PRX302 for Benign Prostatic Hyperplasia

Jul 22, 2014: Nymox Announces Positive Efficacy Results in Phase 3 Repeat Injection Trial of NX-1207 for BPH

Jul 15, 2014: Nymox Announces Completion of Enrollment for Second BPH Re-Injection Study

Jun 17, 2014: Nymox Reports Positive Update on Nerve Sparing and Sexual Function Preservation in Men Treated With NX-1207

Jun 11, 2014: Nymox Reports Positive New Safety Study Data for Phase 3 BPH Drug

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Benign Prostatic Hyperplasia, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Benign Prostatic Hyperplasia – Pipeline by Addex Therapeutics Ltd, H1 2017

Benign Prostatic Hyperplasia – Pipeline by AndroScience Corp, H1 2017

Benign Prostatic Hyperplasia – Pipeline by Aphios Corp, H1 2017

Benign Prostatic Hyperplasia – Pipeline by BCWorld Pharm Co Ltd, H1 2017

Benign Prostatic Hyperplasia – Pipeline by Biolab Farmaceutica Ltda, H1 2017

Benign Prostatic Hyperplasia – Pipeline by Chong Kun Dang Pharmaceutical Corp, H1 2017

Benign Prostatic Hyperplasia – Pipeline by Curadis GmbH, H1 2017

Benign Prostatic Hyperplasia – Pipeline by Dongkook Pharmaceutical Co Ltd, H1 2017

Benign Prostatic Hyperplasia – Pipeline by GL Pharm Tech Corp, H1 2017

Benign Prostatic Hyperplasia – Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2017

Benign Prostatic Hyperplasia – Pipeline by Health Ever Bio-Tech Co Ltd, H1 2017

Benign Prostatic Hyperplasia – Pipeline by Jeil Pharmaceutical Co Ltd, H1 2017

Benign Prostatic Hyperplasia – Pipeline by Kaken Pharmaceutical Co Ltd, H1 2017

Benign Prostatic Hyperplasia – Pipeline by MEI Pharma Inc, H1 2017

Benign Prostatic Hyperplasia – Pipeline by Meiji Seika Pharma Co Ltd, H1 2017

Benign Prostatic Hyperplasia – Pipeline by Mezzion Pharma Co Ltd, H1 2017

Benign Prostatic Hyperplasia – Pipeline by Monosol Rx LLC, H1 2017

Benign Prostatic Hyperplasia – Pipeline by Nymox Pharmaceutical Corp, H1 2017

Benign Prostatic Hyperplasia – Pipeline by Ono Pharmaceutical Co Ltd, H1 2017

Benign Prostatic Hyperplasia – Pipeline by OPKO Health Inc, H1 2017

Benign Prostatic Hyperplasia – Pipeline by SK Chemicals Co Ltd, H1 2017

Benign Prostatic Hyperplasia – Pipeline by SOM Biotech SL, H1 2017

Benign Prostatic Hyperplasia – Pipeline by Sophiris Bio Inc, H1 2017

Benign Prostatic Hyperplasia – Pipeline by Vantia Therapeutics, H1 2017

Benign Prostatic Hyperplasia – Pipeline by XuanZhu Pharma Co Ltd, H1 2017

Benign Prostatic Hyperplasia – Pipeline by Yungjin Pharm Co Ltd, H1 2017

Benign Prostatic Hyperplasia – Dormant Projects, H1 2017

Benign Prostatic Hyperplasia – Dormant Projects, H1 2017 (Contd..1), H1 2017

Benign Prostatic Hyperplasia – Discontinued Products, H1 2017

List of Figures

List of Figures

Number of Products under Development for Benign Prostatic Hyperplasia, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports